

Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

NCT07383025

Status RECRUITING
Sponsor Bristol-Myers Squibb
Enrollment 200 participants

Key Eligibility Criteria

Inclusion (1)

- All obstructive hypertrophic cardiomyopathy (oHCM) patients who initiate treatment with Mavacamten of the approved indications at medical institutions in Japan during enrollment period will be enrolled in this regulatory post-marketing surveillance (PMS) study

Exclusion (1)

- Participants receiving Mavacamten for an off-label indication will be excluded from this PMS study

Locations (1 total)

CMIC Co., Ltd, Tokyo, Japan